A detailed history of Virtus ETF Advisers LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 3,910 shares of BMRN stock, worth $275,967. This represents 0.16% of its overall portfolio holdings.

Number of Shares
3,910
Previous 3,904 0.15%
Holding current value
$275,967
Previous $340,000 5.59%
% of portfolio
0.16%
Previous 0.19%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$74.43 - $92.22 $446 - $553
6 Added 0.15%
3,910 $321,000
Q1 2024

May 15, 2024

BUY
$83.81 - $99.0 $47,101 - $55,638
562 Added 16.82%
3,904 $340,000
Q4 2023

Feb 15, 2024

BUY
$76.22 - $98.51 $9,222 - $11,919
121 Added 3.76%
3,342 $322,000
Q3 2023

Nov 07, 2023

SELL
$85.07 - $94.48 $35,644 - $39,587
-419 Reduced 11.51%
3,221 $284,000
Q2 2023

Aug 14, 2023

BUY
$86.68 - $100.3 $69,430 - $80,340
801 Added 28.21%
3,640 $315,000
Q1 2023

May 15, 2023

BUY
$87.74 - $117.27 $4,123 - $5,511
47 Added 1.68%
2,839 $276,000
Q4 2022

Feb 14, 2023

SELL
$80.93 - $108.63 $40,626 - $54,532
-502 Reduced 15.24%
2,792 $288,000
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $3,943 - $4,653
48 Added 1.48%
3,294 $279,000
Q2 2022

Aug 12, 2022

SELL
$71.48 - $86.85 $88,635 - $107,694
-1,240 Reduced 27.64%
3,246 $269,000
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $75,879 - $96,775
-1,058 Reduced 19.08%
4,486 $396,000
Q3 2021

Nov 15, 2021

SELL
$74.77 - $85.47 $38,132 - $43,589
-510 Reduced 8.42%
5,544 $428,000
Q2 2021

Aug 10, 2021

SELL
$75.51 - $84.79 $112,962 - $126,845
-1,496 Reduced 19.81%
6,054 $505,000
Q1 2021

May 17, 2021

BUY
$74.73 - $90.69 $15,244 - $18,500
204 Added 2.78%
7,550 $570,000
Q4 2020

Feb 12, 2021

BUY
$72.61 - $90.2 $131,932 - $163,893
1,817 Added 32.86%
7,346 $644,000
Q3 2020

Nov 13, 2020

BUY
$71.87 - $131.03 $33,491 - $61,059
466 Added 9.2%
5,529 $421,000
Q2 2020

Aug 05, 2020

SELL
$79.55 - $124.22 $180,896 - $282,476
-2,274 Reduced 30.99%
5,063 $624,000
Q1 2020

May 14, 2020

SELL
$71.37 - $96.85 $44,178 - $59,950
-619 Reduced 7.78%
7,337 $620,000
Q4 2019

Feb 13, 2020

SELL
$64.27 - $86.37 $39,204 - $52,685
-610 Reduced 7.12%
7,956 $673,000
Q3 2019

Nov 12, 2019

SELL
$67.4 - $85.11 $97,527 - $123,154
-1,447 Reduced 14.45%
8,566 $577,000
Q2 2019

Aug 13, 2019

BUY
$80.35 - $93.9 $138,844 - $162,259
1,728 Added 20.86%
10,013 $858,000
Q1 2019

May 14, 2019

BUY
$84.2 - $98.62 $154,254 - $180,671
1,832 Added 28.39%
8,285 $736,000
Q4 2018

Feb 05, 2019

SELL
$80.14 - $106.07 $180,074 - $238,339
-2,247 Reduced 25.83%
6,453 $549,000
Q3 2018

Nov 14, 2018

BUY
$93.92 - $105.72 $55,037 - $61,951
586 Added 7.22%
8,700 $844,000
Q2 2018

Aug 10, 2018

SELL
$76.01 - $99.03 $166,993 - $217,568
-2,197 Reduced 21.31%
8,114 $764,000
Q1 2018

May 14, 2018

SELL
$77.67 - $92.63 $46,524 - $55,485
-599 Reduced 5.49%
10,311 $836,000
Q4 2017

Feb 14, 2018

SELL
$80.76 - $95.13 $28,266 - $33,295
-350 Reduced 3.11%
10,910 $973,000
Q2 2017

Aug 14, 2017

BUY
N/A
11,260
11,260 $1.02 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.